Effcacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: The GLOW7 study

International Journal of COPD

Volumn 10, Issue , 2015, Pages 57-68

  Wang, Chen ^a   Sun, Tieying ^a   Huang, Yijiang ^b   Humphries, Michael ^c   Bai, Lingyan ^c   Li, Lilly ^c   Wang, Qian ^c   Kho, Pearl ^d   Firth, Roz ^d   D’Andrea, Peter ^e  

^a BEIJING HOSPITAL   (China)

^b HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

^c Beijing Novartis Pharma Co Ltd   (China)

^d NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bronchodilation; COPD; Dyspnea; Exacerbations; Glycopyrronium; Health status

Indexed keywords

GLYCOPYRRONIUM BROMIDE; PLACEBO; BRONCHODILATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BRAIN HEMORRHAGE; BRONCHODILATATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHINESE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; DYSURIA; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INHALER; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORNING DOSAGE; MULTICENTER STUDY; PNEUMONIA; PROSTATE HYPERTROPHY; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE ASSESSMENT; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SUDDEN CARDIAC DEATH; SYSTOLIC BLOOD PRESSURE; TRANSITION DYSPNEA INDEX; UPPER RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CLINICAL TRIAL; CONVALESCENCE; DRUG ADMINISTRATION; DRUG EFFECTS; EPIDEMIOLOGY; ETHNOLOGY; INDIA; LUNG; PATHOPHYSIOLOGY; PHILIPPINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; SOUTH KOREA; SPIROMETRY; TIME; TREATMENT OUTCOME; VITAL CAPACITY;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BRONCHODILATOR AGENTS; CHINA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GLYCOPYRROLATE; HEALTH STATUS; HUMANS; INDIA; LUNG; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHILIPPINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOVERY OF FUNCTION; REPUBLIC OF KOREA; SEVERITY OF ILLNESS INDEX; SPIROMETRY; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84920501607     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S72650     Document Type: Article

References (19)

1. Soriano JB, Lamprecht B. Chronic obstructive pulmonary disease: a worldwide problem. Med Clin North Am. 2012;96(4):671–680.
2. Fang X, Wang X, Bai C. COPD in China: The burden and importance of proper management. Chest. 2011;139(4):920–929.
3. Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]. Global Strategy for the Diagnosis, Management and Prevention of COPD; 2014. Available from: http://www.goldcopd.org/. Accessed April 8, 2014.
4. D’Urzo A, Ferguson GT, van Noord JA, et al. Effcacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12:156.
5. Kerwin E, Hebert J, Gallagher N, et al. Effcacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106–1114.
6. D’Urzo A, Kerwin E, Overend T, D’Andrea P, Chen H, Goyal P. Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies. Cur Med Res Opin. 2014;30(3): 493–508.
7. Chapman KR, Beeh KM, Beier J, et al. A blinded evaluation of the eff-cacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulmon Med. 2014;14:4.
8. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the frst dose in patients with COPD: the GLOW3 trial. Int J COPD. 2012;7:503–513.
9. Kirkpatrick d P, Dransfeld MT. Racial and sex differences in chronic obstructive pulmonary disease susceptibility, diagnosis, and treatment. Curr Opin Pulmon Med. 2009;15(2):100–104.
10. Martin A, Badrick E, Mathur R, Hull S. Effect of ethnicity on the prevalence, severity, and management of COPD in general practice. Brit J Gen Pract. 2012;62(595):76–81.
11. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84(3):417–423.
12. Jones R, Ostrem A. Optimising pharmacological maintenance treatment for COPD in primary care. Prim Care Respir J. 2011;20(1):33–45.
13. Roche N, Small M, Broomfeld S, Higgins V, Pollard R. Real World COPD: Association of Morning Symptoms with Clinical and Patient Reported Outcomes. COPD. 2013;10(6):679–686.
14. Westwood M, Bourbeau J, Jones P W, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12:40.
15. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev. 2010;19(116):113–118.
16. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155–162.
17. Jones P W, Rennard SI, Agusti A, et al. Effcacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011;12:55.
18. Matthys H, Pliskevich DA, Bondarchuk OM, Malek FA, Tribanek M, Kieser M. Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPD. Respir Med. 2013;107(5): 691–701.
19. Drollman A, Sechaud R, Pal P, Hara H, Uziel-Fusi S, Winkle P. Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three-period, cross-over, placebo- and positive-controlled study. Int J Clin Pharmacol Ther. 2014;52(9):739–745.